Seguir
Gonzalo Recondo MD PhD
Gonzalo Recondo MD PhD
Instituto Universitario CEMIC
Dirección de correo verificada de cemic.edu.ar
Título
Citado por
Citado por
Año
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
G Recondo, F Facchinetti, KA Olaussen, B Besse, L Friboulet
Nature reviews Clinical oncology 15 (11), 694-708, 2018
3352018
Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ...
Journal of Thoracic Oncology 17 (3), 399-410, 2022
2732022
Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 …
B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ...
JAMA oncology 8 (8), 1160-1168, 2022
2332022
Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC
G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ...
Clinical Cancer Research 26 (11), 2615-2625, 2020
1762020
Targeting MET Dysregulation in Cancer
G Recondo, J Che, PA Jänne, MM Awad
Cancer discovery 10 (7), 922-934, 2020
1642020
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
G Recondo, L Mezquita, F Facchinetti, D Planchard, A Gazzah, L Bigot, ...
Clinical Cancer Research 26 (1), 242-255, 2020
1612020
Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non–small cell lung cancer
B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ...
Clinical cancer research 26 (15), 4135-4142, 2020
1342020
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, ...
Journal for immunotherapy of cancer 9 (3), e001504, 2021
1322021
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
G Lamberti, LF Spurr, Y Li, B Ricciuti, G Recondo, R Umeton, M Nishino, ...
Annals of Oncology 31 (6), 807-814, 2020
942020
MET alterations in NSCLC—current perspectives and future challenges
J Remon, LEL Hendriks, G Mountzios, R García-Campelo, SPL Saw, ...
Journal of Thoracic Oncology 18 (4), 419-435, 2023
802023
Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC
JV Alessi, A Elkrief, B Ricciuti, X Wang, A Cortellini, VR Vaz, G Lamberti, ...
Journal of Thoracic Oncology 18 (6), 731-743, 2023
622023
When tissue is an issue the liquid biopsy is nonissue: a review
J Rodríguez, J Avila, C Rolfo, A Ruíz-Patiño, A Russo, L Ricaurte, ...
Oncology and therapy 9, 89-110, 2021
592021
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
A Ruiz‐Patiño, O Arrieta, AF Cardona, C Martín, LE Raez, ...
Thoracic Cancer 11 (2), 353-361, 2020
542020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung …
L Mezquita, A Swalduz, C Jovelet, S Ortiz-Cuaran, K Howarth, ...
JCO precision oncology 4, 272-282, 2020
532020
High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome
L Mezquita, M Jové, E Nadal, M Kfoury, T Morán, C Ricordel, M Dhooge, ...
Journal of Thoracic Oncology 15 (7), 1232-1239, 2020
492020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
A Pertejo-Fernandez, B Ricciuti, SP Hammond, FM Marty, G Recondo, ...
Lung Cancer 145, 181-185, 2020
472020
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
M Riudavets, E Auclin, M Mosteiro, N Dempsey, M Majem, R Lobefaro, ...
European Journal of Cancer 167, 142-148, 2022
442022
The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
JC Benitez, G Recondo, E Rassy, L Mezquita
The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official …, 2020
432020
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
JB Blaquier, AF Cardona, G Recondo
Frontiers in Oncology 11, 787585, 2021
422021
Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice
AR Solano, FC Cardoso, V Romano, F Perazzo, C Bas, G Recondo, ...
Oncotarget 8 (36), 60487, 2016
402016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20